GlassScriptPhysician profile
Michael P Kahky
NPI 1982706362
$10,814.96
in general payments reported to CMS, 2019-2025
20 companies · $1,460 in 2025
The $1,460 reported for 2025 was more than what 76% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $100 · 2021: $6,750 · 2023: $214 · 2024: $1,879 · 2025: $1,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302 · Travel and Lodging: $1,262 · Honoraria: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.52 |
| Travel and Lodging | $1,262.08 |
| Honoraria | $990.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,749.54 | 2021 | |
| Axogen | $1,787.37 | 2024-2025 | Axoguard Nerve Cap, Axoguard Ha+ Nerve Protector, Axoguard Nerve Protector |
| Davol INC. | $1,055.00 | 2025 | |
| Medtronic USA, INC. | $411.44 | 2019 | |
| Daiichi Sankyo INC. | $255.51 | 2023-2024 | Enhertu |
| Medical Device Business Services, INC. | $100.38 | 2020 | |
| Merit Medical Systems INC | $89.73 | 2025 | Savi Scout |
| Endomagnetics LTD | $70.48 | 2023 | Magtrace, Magseed |
| Sobi, INC | $40.98 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.72 | 2025 | Fruzaqla |
| Stryker Corporation | $30.59 | 2025 | Spy-Phi System |
| Astrazeneca Pharmaceuticals LP | $28.42 | 2025 | Enhertu |
| Agios Pharmaceuticals, INC. | $26.44 | 2025 | Pyrukynd |
| Novartis Pharmaceuticals Corporation | $25.69 | 2024 | |
| Array Biopharma INC | $23.61 | 2024 | Mektovi, Lorbrena, Braftovi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $23.19 | 2024 | Ayvakit |
| Merck Sharp & Dohme LLC | $19.31 | 2024 | Keytruda |
| Genentech USA, INC. | $17.06 | 2024 | Phesgo, Itovebi |
| Geron Corporation | $15.04 | 2025 | Rytelo |
| Glaxosmithkline, LLC. | $13.46 | 2025 | Jemperli, Zejula |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kahky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.